Put your on autopilot.
Metly is the pharma intelligence function your team never had —
running continuously in the background, across every workflow that matters.
What Metly handles
Intelligence across every
pharma workflow
Metly aggregates your pharma data and puts your intelligence workflows on autopilot so your team stays focused on what matters.
Find the right assets before anyone else does
Ask in plain language. Metly searches across regulatory filings, clinical databases, and partnership signals - and returns ranked, contact-ready results.
Know what matters, the moment it changes
Metly monitors competitors continuously. When something relevant happens, it surfaces an alert with strategic context - including how it affects your specific portfolio.
| 2026 | 2027 | |||||||
|---|---|---|---|---|---|---|---|---|
| Asset | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 |
| Injectable | ||||||||
| Asset A | ||||||||
| Asset B NEW | ||||||||
| Oral | ||||||||
| Asset C | ||||||||
| Asset D | ||||||||
| Asset E | ||||||||
Intelligence that writes itself into your work
When a signal lands, Metly doesn't just surface it - it updates your work automatically, so nothing slips through.
New MA granted for generic palbociclib capsules. Three generics already live across EU5 - tender pricing compression expected to intensify.
Our team comes from
The difference
Intelligence that runs,
so you focus on what matters
Platform + People
A platform built by pharma insiders
The Platform
Metly
Metly is where everything comes together. Pipeline shifts, competitive moves, deal signals, market dynamics - tracked, connected, and surfaced in one place. The kind of clarity that transforms how fast your team can move.
The Experts
Intellia
Intellia brings together senior strategists with decades of experience across competitive intelligence, BD, licensing, market access, and medical affairs - so when the stakes are highest, you have the right expertise at the table.
See how our experts can support your strategyThe data is just the beginning.
From internal systems to market signals, Metly connects every source that matters - so high-stakes decisions are never made on half the context.
FAQ
Common questions
-
Pharma teams can't afford to spend weeks building the full picture - and with traditional approaches, it's never truly complete anyway. Metly delivers the intelligence your team needs, faster and more accurately, by pairing our therapeutic area experts with AI-native technology. The result is high-quality, real-time outputs your team can act on immediately.
-
Metly bridges three things that rarely come together: your internal information, the broader external data landscape, and deep therapeutic area expertise. The value isn't in replacing or adding tools - it's in the synthesis. Our team connects those layers and delivers intelligence that's already been validated by people who understand your space, so your team can move faster with confidence.
-
From the first conversation. Every engagement starts with a demo built around your specific therapeutic area and team, so you can see exactly what Metly delivers before committing to anything.
-
Yes. Your internal data is never used to train models or shared across clients. We follow enterprise-grade security standards.
-
Our team brings hands-on experience from Pfizer, Roche, Novartis, AstraZeneca, J&J, Sanofi, Merck, GSK, Eli Lilly, BMS, AbbVie, Bayer, Takeda, and Boehringer - across oncology, rare disease, CNS, immunology, cardiovascular, and more.
-
Yes. For biotech companies, Metly helps with asset diligence, competitive landscape analysis, and market positioning - giving you the intelligence you need to understand where your asset fits, who your competitors are, and how to present your story persuasively when engaging with potential pharma partners.
Get started